JCR Pharmaceuticals Co., Ltd.
【JCR Pharmaceuticals】2027 Q1 Results｜Sales of 9.7 billion yen (Increase of 13.2% YoY)
JCR Pharmaceuticals achieved sales of 9.7 billion yen (up 13.2% YoY) in the first quarter of fiscal 2027, but recorded losses in operating, ordinary, and net income. Increased research and development expenses and progress in new drug development are expected to drive future growth.
Key Figures
- Net sales: 9.7 billion yen (up 13.2% YoY)
- Net income attributable to owners of parent: 1.97 billion yen
- Research and development expenses: 5.888 billion yen (up 75.9% YoY)
AI要約
Financial Results Overview
JCR Pharmaceuticals recorded net sales of 9.7 billion yen (up 13.2% YoY) in the first quarter of fiscal 2027, but reported an operating loss of 2.13 billion yen, an ordinary loss of 2.084 billion yen, and a net loss of 1.97 billion yen. R&D expenses increased by 75.9%, focusing on clinical trial progress and new drug development. The sales increase was driven by strong performance of mucopolysaccharide therapy, with further R&D progress expected to be key for reversing performance.
Outlook and Investment Considerations
The company maintains its earnings forecast for this period, with projected net sales of 45.7 billion yen. However, ongoing increases in R&D investment may lead to continued losses. Progress in clinical trials and R&D expenses are expected to support long-term growth, though short-term losses are likely to persist. The company's assets and liabilities remain stable, and initiatives to strengthen capital policies and expand research bases are ongoing.
JCR Pharmaceuticals Co., Ltd.
Company overview · Stock price · Financial data · All IR
